ADMB-3TMS-PRINACA

  1. Home
  2. Wiki

ADMB-3TMS-PRINACA
Identifiers
  • N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(3-(trimethylsilyl)propyl)-1H-indazole-3-carboxamide
Chemical and physical data
FormulaC20H32N4O2Si
Molar mass388.587 g·mol−1
3D model (JSmol)
  • C[Si](C)(C)CCCn1nc(C(=O)N[C@H](C(=O)N)C(C)(C)C)c2ccccc12
  • InChI=1S/C20H32N4O2Si/c1-20(2,3)17(18(21)25)22-19(26)16-14-10-7-8-11-15(14)24(23-16)12-9-13-27(4,5)6/h7-8,10-11,17H,9,12-13H2,1-6H3,(H2,21,25)(H,22,26)/t17-/m1/s1
  • Key:LJKMOYFTWIBFJI-QGZVFWFLSA-N

ADMB-3TMS-PRINACA (ADB-3TMS-PRINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first identified in Germany in March 2023. It is the first designer drug ever reported that contains a silicon atom.[1]

Legality

[edit]

ADMB-3TMS-PRINACA is illegal in Germany and Italy.[2]

See also

[edit]

References

[edit]
  1. ^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.
  2. ^ "Notizie dalla FNOMCeO" [News from FNOMCeO]. Order of Surgeons and Dentists of the province of Brescia (in Italian). Update of the tables containing the indication of narcotic and psychotropic substances. Inclusion in Table I of the specific indication of the substances: 2'-fluoro-2-fluoro-3-methylfentanyl; N-cyclohexyl butylone; ADMB-3TMSPrinaca


Stub icon

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.